targetedonc.com —  13+ hour, 54+ min ago

...Qian Wang, MD, MPH, assistant professor at Case Western Reserve University, thoracic oncologist at University Hospital Siteman Cancer Center, discusses... ...Qian Wang, MD, MPH, looks at the important metrics related to a patient's smoking history that helps to determine their level of risk for developing... ...Wang discusses these outcomes and how physicians can determine a patient's risk factor of SCLC based on their pack years and intensity of smoking... ...According to the CDC, nearly 9 out of 10 deaths due to lung cancer are caused by smoking cigarettes or exposure to second-hand smoke....

targetedonc.com —  21+ hour, 58+ min ago

...Robert L. Ferris, MD, PhD, discusses what should be done when a trial results in a negative finding.... ...Director Hillman Cancer Center An observation over time as a clinical investigator in the field of oncology is the experience of testing 1 or more... ...Rami Komrokji, MD, discussed the use of JAK inhibitors for treatment of patients with primary myelofibrosis.... ...The field, cooperative group, clinical trial committee, pharmaceutical sponsor, and perhaps even the FDA are at a loss as to whether to scrap the...

targetedonc.com —  1+ day ago

...Program, associate director for clinical investigations at UPMC Hillman Cancer Center, and co director of the Comprehensive Breast Cancer Center,... ...Adam Brufsky, MD, PhD, FACP, professor of medicine at the University of Pittsburgh School of Medicine, associate division chief for the Division... ...is approved for use in combination with an aromatase inhibitor or fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast... ...cancer....

targetedonc.com —  1+ day ago

...If granted approval, fruquintinib will be the first and only highly selective inhibitor of all 3 VEGF receptors to be approved in the United States... ...The FDA has granted priority review of the new drug application (NDA) for fruquintinib (HMPL-013) for the treatment of adult patients with previously... ...Farajallah, MD, head of Global Medical Affairs Oncology at Takeda, in the press release.... ...In the randomized, double-blind, placebo-controlled, phase 3 FRESCO-2 study, 691 patients with refractory mCRC from the United States, Europe, Japan...

targetedonc.com —  1+ day ago

..., Biomarkers & Prevention.1,2 The study was conducted by scientists at the American Cancer Society and Brookdale University Hospital Medical Center... ...in males, where increasing rates were observed in most countries, according to findings from a recent study published in the Journal Cancer Epidemiology... ...president, surveillance and health equity science at the American Cancer Society and senior author of the study, in a press release.1 “Doing this... ...across the world for broad and equitable implementation of known cancer prevention and control interventions,” said Ahmedin Jemal, MD, senior vice...

targetedonc.com —  1+ day ago

...Tanya Dorff, MD, a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology... ...Tanya Dorff, MD, discusses the main findings from a phase 1 study of patients with metastatic castration-resistant prostate cancer.... ...of Hope Pathology Care, and no known contraindications to leukapheresis, steroids, or tocilizumab (Actemra).... ...Baig, MD....

targetedonc.com —  1+ day ago

...advanced non-squamous non–small cell lung cancer (NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy.1 Principal... ...The primary end point of overall survival was not met in the phase 3 SAPPHIRE study of sitravatinib plus nivolumab in patients with advanced non-squamous... ...work like this would not have been possible," said Alan Sandler, MD, chief medical officer.... ..., Mer, as well as split family receptors such as VEGFR2, KIT, and RET....

targetedonc.com —  2+ day, 12+ hour ago

...Kim, MD, MBA (Moderator) Physician-in-Chief, City of Hope Orange County Vice Physician-in-Chief, City of Hope National Medical Center Professor,... ...Kim, MD, MBA, and participants discussed the PACIFIC and PACIFIC-R studies of durvalumab in patients with unresectable stage III non–small cell lung... ...HARRY MENON, DO: I've seen these data before and I agree.... ...BRIAN VICUNA, MD: In the PACIFIC-R data, most of those patients started durvalumab more than 6 weeks after the chemoradiation and their progression-free...

targetedonc.com —  2+ day ago

...transfusion independence compared with erythropoiesis stimulating agents (ESAs) in patients with ESA-naïve, lower-risk myelodysplastic syndrome (MDS... ...Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.... ...author and professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, said during the press briefing... ..., [and this should be] considered a paradigm shift in the treatment of lower-risk MDS–associated anemia,” Guillermo Garcia-Manero, MD, lead study...

targetedonc.com —  2+ day, 14+ hour ago

...In an interview with Targeted Oncology, Andreas Varkaris, MD, PhD, discussed findings from the ReDiscover trial and treating patients with PIK3CA... ...Andreas Varkaris, MD, PhD In the first-in-human phase 1 ReDiscover trial (NCT05216432), treatment with the PI3Kα inhibitor RLY-2608 resulted in sustained... ...However, 1 of the major goals of a phase 1 study is to determine the phase 2 recommended dose,” Andreas Varkaris, MD, PhD, told Targeted OncologyTM... ...Alpelisib was granted FDA approval in 2019 in combination with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2-negative,...